
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Often, parental reassurance is the only intervention necessary for these seizures, but pediatricians can prescribe a new, uncomplicated treatment that prevents recurrence.






